Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Zurletrectinib |
| Synonyms | |
| Therapy Description |
Zurletrectinib is a pan-NTRK inhibitor with activity against resistance mutations, which potentially reduces tumor cell proliferation and tumor growth (PMID: 38902532). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Zurletrectinib | ICP723|ICP 723|ICP-723 | Trk Receptor Inhibitor (Pan) 33 | Zurletrectinib is a pan-NTRK inhibitor with activity against resistance mutations, which potentially reduces tumor cell proliferation and tumor growth (PMID: 38902532). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK2 fusion | Advanced Solid Tumor | predicted - sensitive | Zurletrectinib | Case Reports/Case Series | Actionable | In a Phase I trial, Zurletrectinib treatment was well tolerated and resulted in an overall response rate of 66.7% (4/6, all partial responses) and a disease control rate of 100% (6/6) in patients with NTRK fusion-positive advanced solid tumors, including one partial response with a measurable decrease in the brain lesion (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3106; NCT04685226). | detail... |
| NTRK1 fusion | Advanced Solid Tumor | predicted - sensitive | Zurletrectinib | Case Reports/Case Series | Actionable | In a Phase I trial, Zurletrectinib treatment was well tolerated and resulted in an overall response rate of 66.7% (4/6, all partial responses) and a disease control rate of 100% (6/6) in patients with NTRK fusion-positive advanced solid tumors, including one partial response with a measurable decrease in the brain lesion (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3106; NCT04685226). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05537987 | Phase I | Zurletrectinib | Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |